Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
July 12, 2022
Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
Christina N Fournier
Neurology
|
June 13, 2023
AIMing for Better Tools to Track Disease Progression
Christina N Fournier
Neurology
|
July 30, 2024
Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype
Christina N Fournier
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 20, 2023
The importance of understanding minimal important difference for ALSFRS-R: A reply to 'Do we really need to calculate a minimal important difference for ALSFRS-R?' https://doi.org/10.1080/21678421.2023.2248199
Christina N Fournier, Jonathan D Glass
JAMA Neurology
|
January 10, 2022
Unintended Consequences of Approving Unproven Treatments-Hope, Hype, or Harm?
Jonathan D Glass, Christina N Fournier
Neurology
|
January 30, 2025
The Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: Broke but Not Broken
Christina N Fournier, Colin C Quinn
Muscle & Nerve
|
May 10, 2025
The Necessity of Overcoming Racial Disparities in Amyotrophic Lateral Sclerosis Care and Research
Rocio Carolina Garcia Santibanez, Christina N Fournier
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
December 8, 2022
Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R
Christina N Fournier, Virginia James, Jonathan D Glass
Neurology
|
June 4, 2020
Tau deposition in the spinal cord is not specific for CTE-ALS
Christina N Fournier, Marla Gearing, Jonathan D Glass
Neurology
|
September 19, 2018
Reader response: Pathologic Thr
Jonathan D Glass, Christina N Fournier, Marla Gearing
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
July 12, 2022
Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
Christina N Fournier
Neurology
|
June 13, 2023
AIMing for Better Tools to Track Disease Progression
Christina N Fournier
Neurology
|
July 30, 2024
Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype
Christina N Fournier
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 20, 2023
The importance of understanding minimal important difference for ALSFRS-R: A reply to 'Do we really need to calculate a minimal important difference for ALSFRS-R?' https://doi.org/10.1080/21678421.2023.2248199
Christina N Fournier, Jonathan D Glass
JAMA Neurology
|
January 10, 2022
Unintended Consequences of Approving Unproven Treatments-Hope, Hype, or Harm?
Jonathan D Glass, Christina N Fournier
Neurology
|
January 30, 2025
The Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: Broke but Not Broken
Christina N Fournier, Colin C Quinn
Muscle & Nerve
|
May 10, 2025
The Necessity of Overcoming Racial Disparities in Amyotrophic Lateral Sclerosis Care and Research
Rocio Carolina Garcia Santibanez, Christina N Fournier
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
December 8, 2022
Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R
Christina N Fournier, Virginia James, Jonathan D Glass
Neurology
|
June 4, 2020
Tau deposition in the spinal cord is not specific for CTE-ALS
Christina N Fournier, Marla Gearing, Jonathan D Glass
Neurology
|
September 19, 2018
Reader response: Pathologic Thr
Jonathan D Glass, Christina N Fournier, Marla Gearing
Page
of 4